Phaseline

Companies › ADC Therapeutics

ADC Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 18 registered trials: 12 Phase 2, 5 Phase 1, 1 Phase 3; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Loncastuximab Tesirine
B-lymphocyte antigen CD19 binding agent
CD19Phase 3Relapsed Diffuse Large B-Cell Lymphoma; B-Cell Non-Hodgkin Lymphoma; Relapsed or Refractory Large B-cell Lymphoma; Relapsed Mantle Cell Lymphoma …Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05053659Loncastuximab TesirinePhase 1Relapsed Non Hodgkin LymphomaOncologyNov 2026
NCT05971251Loncastuximab TesirinePhase 1Chronic Lymphocytic LeukemiaOncologyDec 2026
NCT06788964Loncastuximab TesirinePhase 2Relapsed or Refractory Large B-cell LymphomaOncologyMar 2027
NCT05249959Loncastuximab TesirinePhase 2Relapsed Mantle Cell LymphomaOncologyMar 2027
NCT04970901Loncastuximab TesirinePhase 1B-Cell Non-Hodgkin LymphomaOncologyMar 2027
NCT06918912Loncastuximab TesirinePhase 2Diffuse Large B-Cell LymphomaOncologyJun 2027
NCT04998669Loncastuximab TesirinePhase 2Follicular LymphomaOncologyAug 2027
NCT05270057Loncastuximab TesirinePhase 1B-cell LymphomaOncologyOct 2027
NCT05600686Loncastuximab TesirinePhase 2Double-Expressor LymphomaOncologyDec 2027
NCT04384484Loncastuximab TesirinePhase 3Relapsed Diffuse Large B-Cell LymphomaOncologyJun 2028
NCT05296070Loncastuximab TesirinePhase 2Marginal Zone LymphomaOncologyJun 2028
NCT05190705Loncastuximab TesirinePhase 2Waldenstrom MacroglobulinemiaOncologyAug 2028
NCT05672251Loncastuximab TesirinePhase 2Recurrent Diffuse Large B-Cell LymphomaOncologyAug 2029
NCT06607549Loncastuximab TesirinePhase 1Central Nervous System LymphomaOncologyNov 2029
NCT05464719Loncastuximab TesirinePhase 2Large B-cell LymphomaOncologyJan 2030
NCT07197307Loncastuximab TesirinePhase 2Aggressive Diffuse Large B-cell LymphomaOncologyApr 2030
NCT06919939Loncastuximab TesirinePhase 2Large B-cell LymphomaOncologyJan 2031
NCT05991388Loncastuximab TesirinePhase 2B-cell Non Hodgkin LymphomaOncologyMay 2031

From the company's SEC filings

Cash of $189m on 2026-09-30; operating cash outflow about $93m a year; runway about 24 months at that burn, to Oct 2028; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Companies built like this

Immutep S.A.S. Candel Therapeutics Shanghai Ming Ju Biotechnology Actinium Pharmaceuticals Maia Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.